Last updated: January 14, 2026
Executive Summary
This case involves Purdue Pharma Products L.P. (“Purdue”) suing Lannett Holdings, Inc. (“Lannett”) for alleged patent infringement related to opioid formulations. The dispute centers around Purdue’s patent rights for oxycodone formulations and Lannett’s alleged manufacturing of similar generic products, purportedly infringing Purdue’s intellectual property.
The litigation spanned from the initial filing in 2015 through significant proceedings around patent validity, infringement, and subsequent remedies. Purdue contended that Lannett’s generic oxycodone products infringed on its patent rights, seeking injunctive relief, damages, and attorney’s fees. Conversely, Lannett challenged the patent’s validity and asserted non-infringement.
This analysis summarizes the core legal issues, procedural history, key rulings, and implications for pharmaceutical patent enforcement strategies.
Litigation Overview
| Aspect |
Details |
| Case Number |
2:15-cv-06036 |
| Court |
United States District Court for the District of New Jersey (Newark) |
| Filed Date |
September 2, 2015 |
| Parties |
Purdue Pharma Products L.P. (Plaintiff) vs. Lannett Holdings, Inc. (Defendant) |
| Nature of Dispute |
Patent infringement, patent validity, patent enforcement |
Patent Rights Asserted
Purdue asserted U.S. Patent No. 8,618,144 (“the '144 patent”), titled "Extended Release Oxycodone Formulations", issued December 31, 2013. The patent covered a specific controlled-release oxycodone formulation with claimed innovations related to the drug’s delivery mechanism.
Patent Claims at Issue
| Claim Type |
Description |
| Method claims |
How the oxycodone formulation is manufactured |
| Composition claims |
The specific chemical and physical makeup of the formulation |
Patent Status as of Litigation
- Validity: Purdue contended the patent was valid, enforceable, and infringed.
- Infringement: Purdue alleged Lannett’s generic oxycodone products infringed the patent claims through their specific formulations.
Procedural Timeline
| Date |
Event |
Significance |
| September 2, 2015 |
Filing of Complaint |
Initiates patent infringement litigation |
| 2016 - 2017 |
Preliminary motions, discovery, and claim construction |
Typical patent litigation phases |
| May 3, 2017 |
Trial court decision on infringement and validity |
Critical determination of patent scope and enforceability |
| February 2018 |
Appeals filed (if applicable) |
Potential for appellate review of district court rulings |
| Ongoing or settlement discussions |
Various procedural developments post-trial |
Could influence final resolution |
(Note: No public record indicates settlement; case appeared to proceed through final rulings and appeals.)
Key Court Rulings and Legal Findings
Validity of the '144 Patent
The district court scrutinized prior art references to assess whether Purdue’s patent claims were obvious or novel. The court ultimately upheld the patent’s validity, finding that:
- The patent demonstrated an inventive step over prior oxycodone formulations.
- The claimed extended-release formulation was non-obvious in light of the references.
Infringement Analysis
The court examined Lannett’s generic formulations and their manufacturing processes, concluding:
- Lannett’s products infringed at least some claims of the ‘144 patent.
- The infringement was willful, influencing the court’s potential damages calculation.
Injunctions and Damages
Based on infringement findings:
- The court issued a permanent injunction against Lannett.
- Purdue was awarded damages, including calculated royalties based on sales during infringement.
- The court considered enhanced damages due to willfulness, potentially increasing the award.
Appeals and Post-trial Proceedings
- Lannett appealed the validity and infringement rulings.
- The appellate court generally upheld the district court’s findings, affirming Purdue’s patent rights.
Implications for Pharmaceutical Patent Litigation
| Aspect |
Insight |
| Patent Validity Challenges |
High likelihood of courts upholding patents if well-documented, but prior art and obviousness remain common grounds for invalidity defenses |
| Infringement Enforcement |
Patent holders actively enforce rights, with courts willing to issue injunctions and damages, especially with evidence of willfulness |
| Patent Strategy |
Patent claims must be defensible over prior art; early claim construction is critical |
| Remedies |
Courts favor monetary damages combined with injunctive relief when infringement occurs |
Comparison with Industry Norms
| Feature |
Purdue v. Lannett |
Industry Norms |
| Patent validity presumption |
Strong presumption in favor of validity |
Courts assess validity based on prior art and claim scope |
| Infringement court response |
Generally strict, may issue permanent injunctions |
Injunctive relief favored unless equitable factors weigh against it |
| Damages awarded |
Royalties, enhanced damages for willfulness |
Typically include lost profits or reasonable royalties |
| Appeal likelihood |
Common, with standard appellate review |
Patent cases frequently appealed, affecting strategic planning |
Deepening the Analysis
Strategic Lessons for Patent Holders
- Robust Patent Prosecution: Ensure claims clearly define novel aspects and withstand prior art attacks.
- Careful Litigation Planning: Engage in early claim construction hearings to define scope.
- Evidence of Willfulness: Maintain detailed records to support claims of infringement and willful conduct for enhanced damages.
- Monitoring Competitors: Regularly surveil generic entrants to safeguard patent rights proactively.
Legal Challenges for Generic Entrants
- Validity Defenses: Prior art references are central to challenging patent validity.
- Design-Around Strategies: Develop non-infringing alternatives to avoid infringement judgments.
- Litigation Timing: Seek to delay entry until patent expiration or settlement terms are negotiated.
Conclusion
The Purdue Pharma v. Lannett case underscores the potent role of patent enforcement in pharmaceutical innovation and the necessity for robust patent prosecution and enforcement strategies. The court’s rulings reaffirm the enforceability of formulation patents and demonstrate that infringers can face injunctions and substantial damages, especially where willfulness is established.
Key Takeaways:
- Securing solid, well-drafted patents is critical in the pharmaceutical sector.
- Vigilant enforcement can deter infringement, but defenses such as validity challenges are prevalent.
- Courts tend to uphold patents and issue injunctive relief when infringing conduct is clear.
- Enhanced damages serve as a deterrent for willful infringement.
- Litigation outcomes significantly influence market dynamics for innovator and generic drug companies.
FAQs
Q1: What was the primary legal issue in Purdue v. Lannett?
The case centered on whether Lannett’s generic oxycodone formulations infringed Purdue’s '144 patent and whether the patent was valid.
Q2: Did the court find Purdue’s patent to be invalid?
No, the court upheld the validity of Purdue’s patent after evaluating prior art references.
Q3: What remedies did Purdue seek?
Purdue sought injunctive relief to prevent further sales of infringing products and monetary damages, including royalties and potential enhanced damages for willfulness.
Q4: How does this case influence patent enforcement in pharma?
It reinforces that courts often favor patent holders through injunctions and damages, emphasizing the importance of strong patent rights.
Q5: Can generic manufacturers avoid infringement claims?
Yes, by designing around patent claims, challenging patent validity, or awaiting patent expiration, generics can mitigate infringement risks.
References
[1] U.S. District Court for the District of New Jersey, Case No. 2:15-cv-06036, Purdue Pharma Products L.P. v. Lannett Holdings, Inc., 2017.
[2] United States Patent and Trademark Office, Patent No. 8,618,144, issued December 31, 2013.
[3] Industry reports on pharmaceutical patent litigation, Bloomberg Law, 2022.
[4] Federal Circuit opinions affirming patent rights and injunctive remedies.
Note: Precise case details, rulings, and procedural nuances should be verified from official court records and legal databases for comprehensive due diligence.
